Abstract 1500P
Background
Approximately 50% of deaths worldwide occur in an acute hospital setting. Doctors-in-training (DITs) experience death & dying in many forms and settings, and at every stage of their medical training. They often feel unprepared or unsupported when providing this care, which can cause significant distress. Yet, our experience is that DITs do not receive much, if any, specific training or support in approaching these events. The purpose of this study is to establish the training and education received by DITs in Cork University Hospital in dealing with death and explore the concept of spirituality in relation to their own experiences.
Methods
We performed a qualitative survey of DITs using a 27-question electronic survey. Participants answered questions regarding the prior training or education they had received relating to death and dying, their confidence in recognising and managing dying, and their opinion on the adequacy of the training or support available currently. A modified version of the Spiritual Wellbeing Scale (SWBS) questionnaire, a validated tool to provide an overall measure of perceived spiritual quality of life, was used to assess impact on spirituality.
Results
130 DITs responded to our survey (female=75). 67% disagreed or strongly disagreed (n=87) that they have received adequate training in relation to death & dying. Almost half did not feel confident discussing end-of-life care with patients or their families (n=63), and 69% (n=88) felt that support offered after the death of a patient was inadequate. The vast majority agreed or strongly agreed (n=124) that end-of-life care was important to the delivery of acute care. 71% (n=92) reported that the death of a patient had had a personal impact on them. The median Existential Wellbeing Score was 44 (range 24-59), indicating a moderate sense of life satisfaction. Of note, however, 49% (n=64) responded that they felt unsettled about their future.
Conclusions
Patient deaths frequently impact DITs. This survey highlights the importance of improving the training and supports available to DITs in dealing with death & dying. This has the potential to benefit both DITs, through better wellbeing, and their patients, by improving confidence and competence providing end-of-life care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cork University Hospital Medical Oncology Department.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1607P - Association of the lipid biomarker, PCPro, and clinical outcomes in the ENZAMET trial (ANZUP 1304)
Presenter: Lisa Horvath
Session: Poster session 10
1608P - Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial
Presenter: Michael Hofman
Session: Poster session 10
1609P - PSMA-PET and PROMISE re-define stage and risk in patients with prostate cancer
Presenter: Wolfgang Fendler
Session: Poster session 10
1610P - Circulating tumour cell (CTC) enumeration and overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) treated with xaluritamig
Presenter: Andrew Armstrong
Session: Poster session 10
1611P - Haematologic impact of [177Lu]Lu-PSMA-617 versus ARPI change in patients with metastatic castration-resistant prostate cancer in PSMAfore
Presenter: Kim Nguyen Chi
Session: Poster session 10
1612P - Impact of FANCA, ATM, CDK12 alterations on survival in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: David Lorente
Session: Poster session 10
1613P - Clinically advanced prostate cancer (CAPC) featuring BRCA2 loss: A comprehensive genomic profiling (CGP) study
Presenter: Chiara Mercinelli
Session: Poster session 10
1614P - PSA responses and PSMA scan changes after immunotherapy for biochemically recurrent prostate cancer (BCR) without androgen deprivation therapy (ADT)
Presenter: Ravi Madan
Session: Poster session 10
1615P - A new prognostic model of overall survival (OS) in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC)
Presenter: Susan Halabi
Session: Poster session 10